August 10, 2018

Announcements

New Physicians Join Care Centers

I am happy to welcome two new medical and hematological oncologists to our Care Center faculty. Michael Cohenuram, MD, joined the Smilow Cancer Hospital Care Center in Trumbull and Elan Gorshein, DO, JD, MPH, is now caring for patients at our Care Center in Guilford.

Dr. Cohenuram joins Smilow from Praxair Cancer Center at Danbury Hospital where he was Director of the Breast Care Program and Co-Director of Oncology Research. He is a graduate of Dartmouth College and Mount Sinai School of Medicine. He completed his internship and residency at Brown Medical School/Rhode Island Hospital and his fellowship at Yale Cancer Center. At Smilow, he will continue to...
specialize in the care of patients with breast cancer, in addition to thoracic and hematological malignancies.

**Dr. Gorshein** is a graduate of Rutgers University and Rutgers University School of Law. He completed his Doctor of Osteopathic Medicine at Rowan University and a Masters of Public Health degree from Johns Hopkins Bloomberg School of Public Health. He has a special interest in the clinical care of patients with hematological and thoracic malignancies.

Liver, Pancreas and Biliary Symposium
Please join St. Francis Hospital, Yale Cancer Center, and Smilow Cancer Hospital for the 2nd Annual Liver, Pancreas and Biliary CME Symposium on Friday, September 14 at the Connecticut Convention Center. This program is free of charge, hosted by Oncology Services at Saint Francis Hospital and Medical Center.

Learn More >>

**Notables**

**Harvey Risch, MD, PhD.** Professor of Epidemiology and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, is the recipient of the 2018 Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research. Dr. Risch's research has earned international attention for showing the association between colonization by *Helicobacter pylori* and the risk of pancreatic cancer and demonstrating that regular aspirin usage cuts the risk of pancreatic cancer by about one-third.

**Katerina Politi, PhD.** Associate Professor of Pathology and a member of Yale Cancer Center’s Signal Transduction Research Program, has been named the Co-Chair of SWOG’s new Immunotherapy Committee. Katie joins Dr. Ken Grossman of Moffitt Cancer Center in this new role.

Broad Genetic Testing for Advanced Lung Cancer May Not Improve Survival
Read More >>

Getting Under the Skin
Read More >>

Doctors Asking How Much Post-Surgical Follow-up is Needed
Read more >>

Breast Cancer Survivor Preparing for First Closer to Free Ride
Read More >>
Sangini Sheth, MH, MPH, Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, has received a K07 Award from the National Cancer Institute to support her project, Implementation of Inpatient Postpartum Human Papillomavirus Immunization. Dr. Sheth will study the integration of a targeted immunization strategy, inpatient postpartum HPV (IPP-HPV) immunization, into routine care by developing an electronic medical record-based tool.

Peggy Myung, MD, PhD, Assistant Professor of Dermatology and of Pathology and a member of Yale Cancer Center's Signal Transduction Research Program, is one of 18 scientists selected by the Doris Duke Charitable Foundation to receive a Clinical Scientist Development Award. Dr. Myung’s project is titled "Dissecting the epithelial-mesenchymal interactions at the interface of the human skin regeneration and cancer."

Patricia LoRusso, DO, Professor of Medicine and Associate Director for Experimental Therapeutics, Co-Directed the AACR/ASCO Methods in Clinical Cancer Research Workshop in Vail, CO last month. The workshop is intended to help junior faculty and fellows learn the essentials of clinical trial design. Dr. Roy Herbst and Dr. Kurt Schalper also attended and presented at the workshop and were joined by fellows, Tyler Stewart and Deborah Doroshow.

Drs. Stewart, Herbst, Schalper, LoRusso, and Doroshow.

Development Updates

The Thoracic Oncology Program has received a $50,000 donation inspired by the exceptional care of Dr. Rogerio World Lung Cancer Day

Read More >>

Would Routine Genomic Testing For Cancer And Heart Risk Make Economic Sense?

Read More >>

Medical Study Shows Artificial Sweeteners May Have Positive Affects in Colon Cancer Patients

Read More >>
Lilenbaum. The gift will support the ongoing development of our the Thoracic Oncology Program’s ability to enhance best practices, provide clinician education, and increase patient and family support activities. Dr. Daniel Boffa, Clinical Program Leader for the Thoracic Oncology Program, said, “This tribute is a testament to not only Rogerio’s clinical skill set, but his ability to connect with and support patients though challenging diagnoses and treatment.”

Madison Marcus, a student at Amity Regional School District No. 5 in Woodbridge, presented a check to Dr. Navid Hafez, medical oncologist in The Phase I Clinical Trial Infusion Center at Smilow Cancer Hospital. The proceeds from Madison’s June bake sale at the Chef’s Emporium in Orange and online fundraising total over $3,500 and will be directed to patient care in the Phase I Center. Madison’s mother, Paulette (center), is currently receiving care in the Center. Madison is also joined by her father Brad, as well as Mandy DeMerchant, APRN and Binaish Khan, Research Coordinator, from the Phase I Center.

Employee Profile: Stephanie Kulakowski

Join Yale Cancer Center on Facebook

Latest Posts:

Tuesday was a special day for Julia Williams. It marked 5 years since her surgery to remove a recurrence of her breast cancer, but it also represents 5 years of life-special occasions, memories, and conversations that Julia might not have experienced without her care team at Smilow Cancer Hospital.

Volunteers from our Waterford Care Center made sure beachgoers were protected from the sun this weekend by handing out sunscreen and sunglasses. Thank you ladies!
Stephanie Kulakowski, RN, OCN, CHPN, BSN is an Infusion Nurse at the Smilow Cancer Hospital Care Center in Waterbury. Previously, she worked at the Care Center in nearby Torrington for four and a half years, as well as on the 11th floor of the North Pavilion. Most recently, Stephanie accepted the position of Nurse Coordinator at the Waterbury Care Center.

On most days you can find Stephanie setting up and watching over chemotherapy infusions for patients, as well as teaching patients who are newly diagnosed with cancer about their regimen. This entails talking with the patient in a one-on-one meeting and discussing with them what they can expect in regard to their specific treatment regimen.

"There are times when a patient and their family or spouse are in with the doctor, and they feel embarrassed to ask questions that are very personal, or they shy away from addressing concerns they don't want to bother the doctor with," she explains. "The chemotherapy teaching provides the patient with the opportunity to open up in a private setting. Here, we believe in treating the 'whole patient,' and that starts in these meetings. This establishes a trusting relationship between the nurse and patient, which opens the door to continue conversations throughout the entire time they are receiving treatment with us."

The “whole patient” approach extends to assisting with FMLA paperwork, securing transportation to and from appointments, explaining medications, as well as communicating with nutritionists, social workers, and other providers when needed.

Stephanie has been working as a nurse for over eight years, but she originally started out in the “back of the house” side of oncology - working in the lab and diagnosing cancer as a Cytogeneticist. With a degree in Diagnostic Genetics.

From everyone at Smilow Cancer Hospital and Yale Cancer Center - we wish you a safe and wonderful weekend! Make sure to follow us on Twitter (@YaleCancerCenter) and Instagram (@smilowcancerhospital) for all of our latest news updates.

Camp Kesem at Yale University begins on August 13th! Camp Kesem supports children through and beyond a parent's cancer with innovative, fun-filled programs that foster a lasting community. Driven by passionate college student leaders, Camp Kesem operates over 70 free summer camps in 33 states. Follow along as the kids and counselors gear up for camp!
Sciences, she was performing FISH studies, which maps genetic material in human cells, and can help to detect genetic abnormalities associated with cancer. After four years in the lab, Stephanie, who is a natural people-person, decided to shift paths and become a nurse. She completed an 11-month accelerated nursing program at UConn, and then earned her BS in Nursing. A self-described "science geek who loves biology," she enjoys reading oncology publications in her personal time, particularly those pertaining to research and development.

In the eight years since becoming a nurse, Stephanie has developed a profound love for her patients and the oncology field. She has never looked back and in fact, when she is not spending time with family, running, or gardening, you can find her in New Haven helping out on NP-7 on the weekends.

**Funding Opportunities**

**Obesity Policy and Program Evaluation**
This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors and/or weight outcomes in an effort to prevent or reduce obesity.

**Application Deadlines:** August 23, 2018; September 13, 2018; October 10, 2018

[Learn More >]

**Cooperative Human Tissue Network**
The purpose of this FOA, issued by the NCI, is to support the Cooperative Human Tissue Network (CHTN). The goal for CHTN is to collect and distribute to investigators high quality human tissue specimens to facilitate basic and early translational cancer research.

**Application Deadline:** August 28, 2018

[Learn More >]

**NCI Community Oncology Research Program (NCORP) Research Bases**
This FOA solicits applications from institutions/organizations to participate as "Research Bases" for the NCI-supported Community Oncology Research Program (NCORP).

August 31, 2018

[Learn More >]

Interested in learning about the newest insights into the biology of head & neck cancers? Barbara Burtness, MD, Professor of Medicine, has edited the newest publication of Molecular Determinants of Head and Neck Cancer, 2nd Edition, which provides information pertaining to the changing treatment and research questions in the field of head and neck cancers. "Our second edition provides a comprehensive update for this rapidly changing area."

[Read More >]

Our friends from Smilow Rocks visited Smilow this week to spread kindness and encouragement with painted rocks. We love this beautiful, bright, and inspiring design!

[Read More >>]
NCI Community Oncology Research Program (NCORP)
Minority/Underserved Community Sites
This FOA solicits applications from institutions/organizations to participate as "Minority/Underserved Community Sites" for the NCI-supported Community Oncology Research Program (NCORP).

Application Deadline: August 31, 2018
Learn More >>

NCI Community Oncology Research Program (NCORP)
Research Bases
This FOA solicits applications from institutions/organizations to participate as "Research Bases" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). There are three funding opportunities available:

- Research Bases (UG1 Clinical Trial Required)
- Community Sites (UG1 Clinical Trial Required)
- Minority/Underserved Community Sites (UG1 Clinical Trial Required)

Application Deadline: August 31, 2018
Learn More >>

Elsa U. Pardee Foundation Grant
The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer.

Application Deadline: August 31, 2018
Learn More >>

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 and R43/R44)
This FOA encourages both (R43/R44) Small Business Innovation Research and (R41/R42) Small Business Technology Transfer grant applications from small business concerns to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings.

Application Deadline: September 5, 2018
Learn More >>

Follow Yale Cancer Center on Twitter

Congratulations to Dr. Harvey Risch recipient of the 2018 Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research. Dr. Risch's research has earned attention for demonstrating that aspirin usage cuts the risk of #pancreaticcancer by about 1/3.

New @JAMA study led by @CPresGeriOncMD @cpgYALE@DrRoyHerbstYale shows testing for #geneticmutations in tumors of patients with advanced #lungcancer did not improve survival

Tune in to Yale Cancer Answers on @wnpr at 7:30pm to hear Dr.
Gilead Sciences Research Scholars Program in Hematology/Oncology
Grants of up to $130,000 over two years will be awarded to junior faculty researchers for innovative translational research projects in hematology/oncology (with a focus on hematologic malignancies) that can be either based around a clinical trial with strong correlative science or laboratory investigation.
Application Deadline: September 7, 2018
Learn More >>

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01/R21)
The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or AIDS.
Application Deadline: September 7, 2018
Learn More >>

HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01/R21)
The purpose of this FOA is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.
Application Deadline: September 7, 2018
Learn More >>

In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01/R21)
The purpose of this FOA is to stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection and create a better understanding of the immunopathogenic interactions between HBV and HIV.
Application Deadline: September 7, 2018
Learn More >>

Harnessing Big Data to Halt HIV (R01)
The purpose of this FOA is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science.
Application Deadline: September 7, 2018
Learn More >>

Administrative Supplements to Support Cancer Disparity Collaborative Research
The purpose of this trans-NCI FOA is to promote new cancer disparities research among investigators who do not

Steven Bernstein's insight to help smokers kick the daily habit.

What role should #ComplementaryMedicine play in cancer treatment? @sky__john talked to @jocelynmmaminta on @GMCT@WTNH about his latest research in @JAMAOnc.

Dr. Meena Moran comments on a new study in @JNCCN calling for continued aggressive treatment for #breastcancer in women under 40.

It's #WorldLungCancerDay! Dr. Sarah Goldberg talked to @jocelynmmaminta on @GMCT about the latest #lungcancer research and treatment.

@YaleCancer Director Dr. Charles Fuchs on Good Morning CT!

Our Waterford Care Center is at the Hole in the Wall Beach giving out sunscreen and sunglasses today!

Great visit with Congresswoman @rosadelaurow@YaleCancer!!

Many thanks to @Hyundai and @hopeonwheels for $100,000 grant given to Dr. Shilpa Hattangadi @YaleCancer at Smilow Cancer Hospital for pediatric cancer research!

@YaleCancer Dr. Barbara Burtness has written a 2nd edition about advances in the understanding of #headandneckcancer biology and new therapies available for patients.

Calendar

YCC Seminar
normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers.

**Application Deadline:** September 10, 2018

Learn More >>

### DoD Breast Cancer Research Program Funding Opportunities

Applications to the FY18 BCRP are being solicited for the DHA. The BCRP supports innovative, high-impact research focused on ending breast cancer.

- **Breakthrough Award Level 3 & 4:** Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. Preproposal Due: September 14, 2018
- **Breakthrough Award Level 1 & 2:** Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. **LOI Due:** November 1, 2018

Learn More >>

### Prostate Cancer Research Program Funding Opportunities

The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.

- **Health Disparity Research Award - Letter of Intent Due:** September 20, 2018
- **Health Disparity Scholar Award - Letter of Intent Due:** September 20, 2018

Learn More >>

### Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25)

The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the nation's biomedical, behavioral, and clinical research workforce.

**Application Deadline:** September 25, 2018

Learn More >>

### Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25)

The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the nation's biomedical, behavioral, and clinical research workforce.

**Application Deadline:** September 25, 2018
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01)
This FOA encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes.
Application Deadline: October 5, 2018
Learn More >>

Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54 Clinical Trials Optional)
The purpose of this FOA is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance the diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness.
Application Deadline: October 9, 2018
Learn More >>

Administrative Supplements for Research on Dietary Supplements
This FOA announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention.
Application Deadline: October 15, 2018
Learn More >>

Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents
This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of quantitative analytical methods.
Application Deadline: October 15, 2018
Learn More >>

Recent Publications
MiRNA-BD: an evidence-based bioinformatics model and software tool for microRNA biomarker discovery.
Lin Y, Wu W, Sun Z, Shen L, Shen B.

Smilow Art Therapy Summer Thursdays
August 16; 4PM
NP4-101A
Learn More >>

Smilow Screening & Prevention Informational Table
August 17; 12PM
Scantlebury Park
8th Annual Family Fun & Fitness Day / New Haven Healthy Start
Learn More >>

Smilow Screening & Prevention Informational Table
August 18; 2PM
Scantlebury Park
YCCI Community Health Fair
Learn More >>

Yale Cancer Answers
August 19; 7:30PM
WNPR
New Advances in Brain Tumor Treatments and Trials
Zachary Corbin, MD
Learn More >>

Smilow Screening & Prevention Informational Table
August 20; 10AM
Edgewood Park
Packs for Pals Community Fair
Learn More >>

YCC Seminar
August 21; 12PM
BCMM 206/208
KDM5 histone demethylases repress immune response via suppression of STING.

Sno-derived RNAs are prevalent molecular markers of cancer immunity.

How I treat breast cancer with positive lymph nodes.
Chagpar AB.

Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.

Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy.
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD.

Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.
Bugide S, Janostiak R, Wajapeyee N.
Hormone producing gynecological tumors: pathologic entities and clinical significance.
Boto AN, Hui P.
Read More >>

Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.
Read More >>

Mutations in the Drosophila tricellular junction protein M6 synergize with RasV12 to induce apical cell delamination and invasion.
Dunn BS, Rush L, Lu JY, Xu T.
Read More >>

A Clinical Care Pathway to Reduce ICU Usage in Head and Neck Microvascular Reconstruction.
Morse E, Henderson C, Carafeno T, Dibble J, Longley P, Chan E, Judson B, Yarborough WG, Sasaki C, Mehra S.
Read More >>

Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations.
Morse E, Judson B, Husain Z, Burtness B, Yarborough WG, Sasaki C, Cheraghliou S, Mehra S.
Read More >>

Determinants of Active Surveillance in Patients with Small Renal Masses.
Urology. 2018 Jul 27.
Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.

Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors.

Aplastic anemia: etiology, molecular pathogenesis and emerging concepts.

Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.